Windows 8.1 Preview ISOs are available for download

Ah! I didn't know there's Windows 8.1
The ISOs should be helpful if you wish to 'futureproof' your spanking new application in the latest windows or test exisiting apps to see if they might break in the new win8.1

and *cough*usingtheisosasVMsinyourpreferredLinuxenvbutyoukindaneedawindozemachinetodothosetasksthatyoucan'tdoinlinuxcosotherprogrammershaven'theardofbuildingformultiplatformmachines*cough*

well another good reason to use it is that I am pretty sure this ain't happening in Mac or Linux

Microsoft is adding native support for 3D printing as part of the Windows 8.1 update, making it possible to print directly from an app to a 3D printer. The company is announcing the new feature this morning, working with partners including MakerBot Industries, 3D Systems, Afinia, AutoDesk, Netfabb and others.
http://www.geekwire.com/2013/dimension-windows-microsoft-adds-3d-printing-support/


:)

Go http://msdn.microsoft.com/en-us/windows/apps/bg182409 now!
loving the 1.5 Mb/s download here

The $1000 myth | opiniomics

*chuckles* I guess only people outside of sequencing needs to be educated on this .. 

Now, it's possible Broad, BGI, Sanger etc can get below $1000 for the reagents due to sheer economies of scale and special deals they have with sequencing companies – but then remember they have to add in those extra charges (2-5) above.

Obviously, Illumina don't charge themselves list price for reagents, and nor do LifeTech, so it's possible that they themselves can sequence 30x human genomes and just pay whatever it costs to make the reagents and build the machines; but this is not reality and it's not really how sequencing is done today.  These guys want to sell machines and reagents, they don't want to be sequencing facilities, plus they still have to pay the staff, pay the bills, make a profit and return money to investors.
http://biomickwatson.wordpress.com/2013/06/18/the-1000-myth/

A cloud platform for virtual screening?

Chanced on a blog post inspired by https://www.quantconnect.com/ . Overington suggests the possibility of adopting the model for virtual screening informatics.

For our field I think a SV detection platform would be most 'lucrative'. I would argue that SVs hold an even more important position in contributing to human diversity and disease than the relatively-easier-to-characterize SNPs. I think that  #usegalaxy workflow/pipelines might be able to provide a basic framework to build on for people to try to tackle characterization of SVs across multiple sources of sequence data that's publicly available. The problem is who will host the data and platform


The ChEMBL-og - Open Data For Drug Discovery: A cloud platform for virtual screening?: Anyway, have a look, it looks really nice, and got me thinking that it would be a great model for a virtual screening/drug repositioning informatics biotech, where the platform 'brokers' a tournament of approaches coded against data held on a data/compute cloud

Each time when I change jobs, I will have to go through the adventure (and sometimes pain) to relearn about the computing resources available to me (personal), lab (small sharing pool), and the entire institute/company/school (Not enought to go around usually).
Depending on the job scope / number of cores / length of the job I would then setup the computing resources to run on either of the 3 resources available to me.
Sometimes, grant money appears magically and I am asked by my boss what do I need to buy (ok TBH  this is rare). Hence it's always nice to keep a lookout on what's available on the market and who's using what to do what. So that one day when grant money magically appears, I won't be stumped for an answer.

excerpted from the provisional PDF are three points which I agree fully

Three GiB of RAM per core is not enough
you won't believe the number of things I tried to do to outsmart the 'system' just to squeeze enough ram for my jobs. Like looking for parallel queues which often have a bigger amount of RAM allocation. Doing tests for small jobs to make sure it runs ok before scaling it up and have it fail after two days due to insufficient RAM.
MPI is not widely used in NGS analysis
A lot of the queues in the university shared resource has ample resources for my jobs but were reserved for MPI jobs. Hence I can't touch those at all.
A central file system helps keep redundancy to a minimum
balancing RAM / compute cores to make the job splitting efficient was one thing. The other pain in the aXX was having to move files out of the compute node as soon as the job is done and clear all intermediate files. There were times where the job might have failed but as I deleted the intermediate files in the last step of the pipeline bash script, I wasn't able to be sure it ran to completion. In the end I had to rerun the job and keeping the intermediate files


anyway for more info you can check out the below

http://www.gigasciencejournal.com/content/2/1/9/abstract

Lessons learned from implementing a national infrastructure in Sweden for storage and analysis of next-generation sequencing data

Samuel Lampa, Martin Dahlö, Pall I Olason, Jonas Hagberg and Ola Spjuth

For all author emails, please log on.

GigaScience 2013, 2:9 doi:10.1186/2047-217X-2-9

Published: 25 June 2013

Abstract (provisional)

Analyzing and storing data and results from next-generation sequencing (NGS) experiments is a challenging task, hampered by ever-increasing data volumes and frequent updates of analysis methods and tools. Storage and computation have grown beyond the capacity of personal computers and there is a need for suitable e-infrastructures for processing. Here we describe UPPNEX, an implementation of such an infrastructure, tailored to the needs of data storage and analysis of NGS data in Sweden serving various labs and multiple instruments from the major sequencing technology platforms. UPPNEX comprises resources for high-performance computing, large-scale and high-availability storage, an extensive bioinformatics software suite, up-to-date reference genomes and annotations, a support function with system and application experts as well as a web portal and support ticket system. UPPNEX applications are numerous and diverse, and include whole genome-, de novo- and exome sequencing, targeted resequencing, SNP discovery, RNASeq, and methylation analysis. There are over 300 projects that utilize UPPNEX and include large undertakings such as the sequencing of the flycatcher and Norwegian spruce. We describe the strategic decisions made when investing in hardware, setting up maintenance and support, allocating resources, and illustrate major challenges such as managing data growth. We conclude with summarizing our experiences and observations with UPPNEX to date, providing insights into the successful and less successful decisions made.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Data Analyst - Asia Product Vigilance Procter & Gamble - SG-Singapore-Singapore (Singapore)

Haven't been looking at jobs for a while .. here's something that caught my eye .. typically I feel that pharma jobs are more detailed and pertinent in their hiring criteria since they have a very good idea of what kind of skills they want for the person they are hiring .. it's no different here .. so not much of a surprise. The biggest surprise was that they would only consider a bachelor's degree holder only if they have 8 years of relevant experience.  Whether that's equivalent, I shall leave you to decide ..

http://www.linkedin.com/jobs?viewJob=&jobId=5784577

Job Description

Description

This position will be part of the Global Safety Surveillance and Analysis organization. The successful job incumbent will query consumer complaints and adverse health effects databases for purposes of signal detection and ad hoc requests by internal customers (Product Vigilance-PV Managers, Product Development, Business Team, Central Product Safety, etc.), and develop customized reports to interpret data and identify potential safety issues as well as health concerns for in-market products.

Responsibilities

- Querying large health effects datasets to identify safety signals and trends

- Generating periodic safety reports with different levels of specificities
and focuses

- Summarizing and interpreting safety data together with PV managers

- Developing and applying statistical methods for various data analysis needs

- Continuously improving current data mining methodology, tools, and systems together with global work force.
Qualifications

- Masters Degree in applied statistics or data mining fields with relevant data analysis experiences or advanced degree in human health or clinically oriented informatics research. Bachelor Degree holders with at least 8 years of relevant years can also be considered.

- Experience with electronic data capture systems and analytical tools, including manipulation and visualization of data using reporting tools. Statistical analysis and database operation experience is preferred.

- Excellent written and oral communication skills in English, with emphasis on communication of human health relevance, safety and clinical information

- Excellent organization skills, attention to details and ability to manage complex systems.

- Good collaboration skills: experience establishing and maintaining global and cross-functional working relationships.

Company Description

About Procter & Gamble

P&G serves approximately 4.6 billion people around the world with its brands. The Company has one of the strongest portfolios of trusted, quality, leadership brands, including Pampers®, Tide®, Ariel®, Always®, Whisper®, Pantene®, Mach3®, Bounty®, Dawn®, Fairy®, Gain®, Charmin®, Downy®, Lenor®, Iams®, Crest®, Oral-B®, Duracell®, Olay®, Head & Shoulders®, Wella®, Gillette®, Braun®, Fusion®, Ace®, Febreze®, Ambi Pur®, SK-II®, and Vicks®. The P&G community includes operations in approximately 75 countries worldwide. Please visit Us.experiencePG.com for the latest news and in-depth information about a career at P&G!

Additional Information

Posted:

June 17, 2013

Type:

Full-time

Experience:

Entry level

Functions:

Science, Research 

Industries:

Consumer Goods 

Employer Job ID:

RND00002464-en

Job ID:

5784577

Bloomberg: MRI for $7,332 Shows Wide Variety in U.S. Medical Costs

There was a kaggle contest for making predictions on patient data to predict return visits if i recall correctly. Wonder what was the aim of this "datapalooza" but this side finding does raises questions about healthcare costing. 

Alternatively it might just simply mean that some numbers were wrongly entered into the database. I for one have always been lost in the maze of medical receipts where some items are grouped together and some are separate. 

Lesson to be learnt. Important to learn about your primary data.  

From Bloomberg, 4 Jun, 2013 4:45:54 AM

The costs of outpatient hospital care vary widely for typical services such as an MRI, according to data released by the U.S. government.

To read the entire article, go to http://bloom.bg/15w43FN
Sent from the Bloomberg iPad application. Download the free application at http://itunes.apple.com/us/app/bloomberg-for-ipad/id364304764?mt=8

Sent from my iPad

Bloomberg: Michael Douglas Oral Sex Cancer Claim Spurs Vaccine Calls

Wow another celebrity "medical advice endorsement" 

but it makes sense to immunise guys for the purpose of stemming the spread of the disease and lowering costs of the vaccine for a prevalent disease imho 

From Bloomberg, 3 Jun, 2013 8:51:50 PM

Michael Douglas's claim that oral sex led to his throat cancer is spurring calls to vaccinate more boys as well as girls against the human papilloma virus that causes the malignancy.

To read the entire article, go to http://www.bloomberg.com/news/2013-06-03/michael-douglas-oral-sex-cancer-claim-spurs-vaccine-calls.html
Sent from the Bloomberg iPad application. Download the free application at http://itunes.apple.com/us/app/bloomberg-for-ipad/id364304764?mt=8

Sent from my iPad